WuXi Discovery Services

Despite the resurgence of interest in peptide therapeutics for historically “undruggable” targets, de novo discovery of peptide ligands remains a challenge. Unlike traditional technologies, DNA-encoded libraries (DELs) predominantly employ unnatural amino acids, and the resulting cyclic peptide-like molecules which are generated display a wider range of chemical space and smaller ring sizes with improved physicochemical properties. At this year’s TIDES USA conference, WuXi AppTec presented a poster showcasing the effectiveness of DELs for the discovery of macrocyclic peptides and the identification of tumor cell-specific peptide ligands as potential targeting moieties to deliver oligonucleotides. Click this link 👇 to download our poster: https://lnkd.in/eA-bQdS9 #Biotech #DrugDiscovery #DEL #Peptides #Macrocyclic #TIDES

The hepatobiliary system (comprised of the liver, gallbladder, and bile ducts) plays an important role in digestion and in the biotransformation and disposition of endogenous molecules and drugs. Hepatobiliary diseases range from minor infection or scarring to serious conditions such as cancer. At this year’s EASL conference, WuXi AppTec showcased our comprehensive platform of hepatobiliary-related services, such as our CAP-certified pathology laboratory and our extensive panel of animal disease models, including NAFLD, fibrosis, cirrhosis, and a clinically relevant NASH mouse model. Click this link 👇 to learn more: https://lnkd.in/e5XKVjdJ #Hepatobiliary #LiverDisease #NAFLD #LiverFibrosis #Cirrhosis #NASH #EASL

We are excited to announce that Crelux, the structure-based drug discovery specialists of WuXi AppTec Discovery Biology, is relocating its laboratories and offices to a state-of-the-art life science building in Munich-Gräfelfing. With customized spatial and technical infrastructure, several operative units of WuXi Biology and WuXi AppTec LTD can now work side by side in the center of the Munich biotech community to further expand WuXi AppTec’s Open Service Platform, already enabling thousands of innovative clients around the globe. Click this link 👇to read more: https://lnkd.in/gwGBfYkv #Crelux #Munich #Biotech #BioPharma #DrugDiscovery #StructuralBiology

G-protein coupled receptors (GPCRs) play a pivotal role in signaling pathways, and these transmembrane proteins represent an important drug target class. The majority of approved drugs that target GPCRs bind to traditional orthosteric sites. In a recent publication in Nature, Professor Brian Kobilka and his team at Stanford University successfully identified selective negative allosteric modulators (NAMs) for the μ-opioid receptor (μOR) using DNA-encoded library (DEL) technology. The compound, 368, was discovered directly from WuXi AppTec's DEL product and exhibited permeability across the blood-brain barrier, as well as efficacy in both in vitro and in vivo models without any modifications. This work exemplifies an effective application of DEL technology in identifying novel hits for GPCR targets. Click this link 👇 to view the abstract: https://lnkd.in/e3GrvQUf Click this link 👇 for more information on WuXi AppTec’s DEL screening platform: https://lnkd.in/gE3VVzf2 #Biotech #GPCR #DEL #DrugDiscovery #OpioidReceptor

Join our upcoming webinar to learn about research strategies for the discovery of targeted protein degraders. Using an event-driven pharmacology approach, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular self-destruction mechanisms. This technology is enabling researchers to pursue targets that were previously considered undruggable and to address the resistance issue of small molecule inhibitors. Since 2016, WuXi AppTec has built a comprehensive TPD discovery service platform to investigate the full functional cycle of protein degraders - from binary/ternary complex formation to target ubiquitination and degradation. Don’t miss your chance to ask questions to our experts! Click this link 👇to register for our webinar: https://lnkd.in/egx4kZAy

In the last decade, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular self-destruction mechanisms. Join WuXi AppTec at the 4th Annual Induced Proximity-Based Drug Discovery Summit, covering the latest advancements in proximity-induced target protein degradation (TPD). Since 2016, WuXi AppTec has built a comprehensive TPD discovery service platform, adept in over 20 assay formats to investigate the full TPD function cycle from binary/ternary complex formation and POI ubiquitination to degradation. Our broad and deep expertise spans across diverse TPD modalities, including PROTAC®, molecular glues, AUTAC/ATTEC, LYTAC, DUBTAC, and PHICS. Visit us in the exhibit area, where our experts welcome the opportunity to discuss your projects! Click this link 👇to prearrange a dedicated one-on-one meeting: https://lnkd.in/erEZEJ6u #TPD #PROTAC #ProteinDegraders #MolecularGlues #LYTAC #DUBTAC #PHICS

Inhibition of the Werner syndrome RecQ helicase (WRN) is a promising approach for the treatment of cancers commonly associated with microsatellite instability. To support drug discovery programs, we have established off-the-shelf crystallization systems to enable the determination of high-resolution X-ray crystal structures with a short turnaround time. Together with our protein production service and off-the-shelf biochemical and biophysical assays, we can provide a broad range of data to accelerate and support your drug development programs. The WuXi AppTec Discovery Biology Structural Biology platform provides a wide range of X-ray crystallography and cryo-EM services. With decades of experience in structural biology and state-of-the-art infrastructure in Munich (Germany) and Suzhou (China), we are the ideal partner for your drug discovery program. Click this link 👇 to learn more about our structural biology services: https://lnkd.in/eMFWCGVq #Biophysical #Helicase #RecQ #WRN #Crystallography #CryoEM

Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases and is marked by high malignancy, rapid progression, and poor prognosis. Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand that is highly expressed in SCLC and other neuroendocrine tumors but minimally expressed in normal tissues. As a result, DLL3 is considered a potential therapeutic target for SCLC. Chimeric antigen receptor T-cell (CAR-T) therapy has recently shown great promise in preclinical studies for treating SCLC. WuXi Biology scientists successfully developed DLL3 CAR-T cells via lentiviral transduction, and in our latest issue of OncoWuXi Express we present a case study demonstrating the antitumor efficacy of DLL3 CAR-T in a SHP-77-Luc orthotopic lung model. Click this link 👇 to view our case study. https://lnkd.in/eEgYw2WN #Biotech #Biopharma #DrugDiscovery #CART #DLL3 #SCLC #Notch #Antitumor

As part of our neurobiology services platform, WuXi AppTec offers a comprehensive panel of advanced technologies and validated disease models to help project teams overcome the challenges in predicting the efficacy and safety of their lead candidates. We provide a full spectrum of neurological coverage, from neurodegenerative diseases and neuropsychiatric disorders to sensory and rare disorders. Our in-depth analytics allows researchers to harness the insights of behavioral and neurophysiological assessments for a data-driven approach to drug discovery. Click below to view our case studies, including the application of a clinical biomarker in a mouse model for Alzheimer’s. Click 👇 to learn more. https://lnkd.in/ed4m8KQk #DrugDiscovery #CNS #Neurobiology #Neurodegenerative #Neurosensory